Publicaciones › Edema macular diabético y sus tratamientos
Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas
Tratamiento del hemangioblastoma retiniano de von Hippel-Lindau con el inhibidor del receptor de factor de crecimiento vascular endotelial SU5416 es más efectivo para el edema macular asociado que para los hemangioblastomas
| Año | 2003 |
|---|---|
| Fuente | American journal of ophthalmology |
| Tipo | article · Case Reports, Journal Article, Research Support, Non-U.S. Gov't |
| Autores (6) | Jean François Girmens, Ali Erginay, Pascale Massin, Paul Scigalla, Alain Gaudric, Stéphane Richard |
| Posición de Erginay | 2 de 6 |
| Citas | 111 (OpenAlex) |
| Enlaces | DOI 10.1016/s0002-9394(03)00101-6 · PubMed 12834696 · OpenAlex |
| Líneas | Edema macular diabético y sus tratamientos Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo |
En pocas palabras
Se estudió el efecto del inhibidor del receptor de factor de crecimiento vascular endotelial SU5416 en un caso de hemangioblastoma retiniano de von Hippel-Lindau refractario. El tratamiento mejoró significativamente el edema macular asociado, pero no redujo el tamaño de los hemangioblastomas. La visión del paciente mejoró temporalmente durante el tratamiento.
Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.
Resumen original
To test the efficacy of the novel vascular endothelial growth factor (VEGF) receptor inhibitor SU5416, in a case of refractory von Hippel-Lindau (VHL) retinal hemangioblastoma (RHB). Interventional case report. Patient included in a multicenter phase II trial. A 30-year-old woman presenting with VHL disease and multiple RHB on her only eye, refractory to conventional treatments, had decreased visual acuity due to cystoid macular edema (CME). SU5416 was administered intravenously for 7 months. Best-corrected visual acuity (BCVA) and macular thickness were measured by optical coherence tomography. Under treatment, the size of the RHB did not change, but CME improved significantly. Best-corrected visual acuity rose from 20/40 to 20/25. However, CME recurred after the end of the treatment. The VEGF receptor inhibitor SU5416 failed to reduce the size of RHB but was very effective for the associated CME.